Recombinant zoster vaccine should go on NIP, says PBAC

The vaccine costs up to $600 on the private market for a two-dose course

The recombinant zoster vaccine Shingrix has received PBAC approval for patients aged 70 and for immunocompromised adults at high risk of zoster infection. 

Aboriginal and Torres Strait Islander patients aged 50 and older should also be eligible for Shingrix under the National Immunisation Program (NIP), the PBAC said on Friday.